Reassessing adverse prognosis of acute myeloid leukemia harboring BCR::ABL1 in the era of tyrosine kinase inhibitors: A real‐world analysis from the PETHEMA registry

Key Points

• The research aims to evaluate the prognosis of acute myeloid leukemia (AML) patients with BCR::ABL1 in light of tyrosine kinase inhibitors (TKIs).
• Data analysis from the PETHEMA registry
• Comparison of outcomes with and without TKI
• Classification of patients into risk groups
• Improved outcomes observed with TKI addition to chemotherapy
• AML patients with BCR::ABL1 may benefit from re-classification to intermediate-risk
• Findings suggest a need for larger studies to confirm results